PRF Technologies Ltd. (PRFX)

PRF Technologies operates a deliberate duality: a pharmaceutical division reformulating established therapies using proprietary drug-delivery systems, and an energy technology platform applying artificial intelligence to solar asset management and revenue forecasting. The company’s ordinary shares trade on Nasdaq under the symbol PRFX. The pairing is unconventional — pain relief and solar analytics share little surface in common — but both rest on the same premise: that precision engineering of existing tools creates value where broad approaches have left money on the table.

“Two high-impact sectors applied precision technology applied to high-impact sectors where broad approaches have left gaps.”

The pharmaceutical play: drop-less delivery for surgery

The company’s healthcare focus targets post-surgical pain — specifically the hours and days after ophthalmic surgery. Cataract removal is one of the most common surgical procedures worldwide, and patients typically leave the operating theatre needing pain management and anti-inflammatory treatment. Traditional approach: eye drops, which patients must instil repeatedly, at risk of missing doses, overdosing, or contaminating the bottle. The irritation and compliance burden are real, and opioid alternatives remain limited.

PRF’s solution is OcuRing-K, a bio-erodible ring implant placed on the lens at the time of surgery, releasing medication directly into the eye over weeks. The device eliminates the need for drops entirely — no compliance risk, no contamination, localized delivery at high concentration. The underlying technology is an extended-release delivery platform that can carry multiple active ingredients; the company acquired it through a majority investment in LayerBio and is advancing OcuRing-K through preclinical work and regulatory planning toward an IND (Investigational New Drug) application.

The company also holds PRF-110, a viscous oil-based solution that instils into the surgical wound to provide localized post-operative analgesia. Both programs target the same gap: the shift away from systemic pain relief (particularly opioids) toward localized, delivered therapy — a trend that regulatory bodies and health systems actively encourage.

The energy platform: monetizing solar forecasts

DeepSolar, acquired in recent years, addresses a parallel problem in renewable energy: most solar operators have real-time production data but lack the intelligence to act on it. Grid operators and energy traders face a bottleneck: they can see what a solar plant is producing now, but forecasting what it will produce in the next hour, day, or week — and therefore what energy to sell, where, and when — has been either manual or crude. Wind speed, cloud cover, historical patterns, and grid pricing all matter; integrating them into real-time decision support is the gap.

DeepSolar Predict is PRF’s answer: a platform that ingests production telemetry, weather forecasting, and wholesale energy pricing, then recommends real-time actions for storage discharge, grid export, or load shifting. The value proposition is measurable: a solar operator with intraday price volatility can improve realized revenue by optimizing when to sell. For utility-scale and distributed solar portfolios, even single-digit percentage uplift across a large fleet scales to millions.

The platform includes Smart TDD (temperature-derived data analytics) and automated reporting tools for asset management and compliance. The company is in the early commercialization phase, advancing toward revenue-generating contracts with energy operators.

Where the moat lies—and where it doesn’t

Neither business has an obvious structural moat. OcuRing-K’s moat, if it succeeds, will rest on the patent estate around the delivery mechanism and, later, regulatory approval and the clinical data backing it — barriers that are real but temporary (patents expire, competitors develop alternatives, clinical evidence is replicable). Success depends on clinical efficacy and regulatory approval still ahead; the company is years from revenue.

DeepSolar sits in a crowded market of energy-forecasting platforms, from weather specialists to utility software vendors. The company’s advantage lies in focus and speed to market rather than proprietary data or unique algorithms. No licensing of weather data or historical production records is exclusive to PRF; the differentiation is in tooling and user experience, which competitors can replicate. Scale and customer lock-in (once installed across a utility’s fleet, switching costs rise) matter more than patent protection.

The real competitive advantage for PRF as a whole is portfolio risk. A single-product biotech that fails on Phase 2 efficacy is dead. A single-platform energy software company competes on features and UX against entrenched incumbents. PRF’s duality means neither business is the whole story — failure in one does not eliminate the other. That is strategic optionality, not a durable moat.

Financial footing and clinical progression

The company ended 2025 with approximately $4.1 million in cash and positive working capital of $2.0 million — a tight position that underscores the importance of near-term progress. Research and development spending has declined sharply (from $11.7 million in 2024 to $1.1 million in 2025), a reduction that may reflect either portfolio optimization or resource constraint; the company reported a net loss of $4.8 million for 2025, significantly improved from $14.6 million in 2024.

The pharmaceutical programs are pre-revenue and pre-approval, meaning clinical data and regulatory milestones drive share price more than operational metrics. The DeepSolar business is in early commercialization; the company is pursuing pilot deployments and early customer relationships.

How to research PRF Technologies

Start with the most recent 10-K filing (SEC CIK 0001801834) to understand current cash position, pipeline stage, and the relative strategic weight the company places on each division. Earnings calls and press releases announce clinical milestones (IND applications, Phase 1 safety data) and DeepSolar contract wins or pilot deployments. Watch for progress on OcuRing-K toward an IND filing and early commercial traction in the energy analytics platform. The pharmaceutical development timeline is measured in years; changes in that trajectory move the stock more than quarterly revenue figures for a company with minimal near-term sales.